Literature DB >> 6752033

Effect of Escherichia coli alpha-hemolysin on human peripheral leukocyte function in vitro.

S J Cavalieri, I S Snyder.   

Abstract

To gain further evidence for the role of the Escherichia coli alpha-hemolysin in pathogenesis, its in vitro effects on human peripheral leukocyte function were studied. Leukocytes exposed to low doses of alpha-hemolysin responded with a marked chemiluminescence response, indicating activation of oxidative metabolism. This response was time and dose dependent. Pretreatment of leukocytes with doses of alpha-hemolysin at which nearly 80% of the cells survived decreased the ability of the cells to phagocytize bacteria and particles and to undergo chemotaxis. Premature activation of leukocytes and inhibition of phagocytosis and chemotaxis by alpha-hemolysin, if they occur in vivo, would greatly enhance the survival of an invading E. coli strain.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6752033      PMCID: PMC347633          DOI: 10.1128/iai.37.3.966-974.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Suppression of chemotatic activity of human neutrophils by streptolysin O.

Authors:  B R Andersen; D E Van Epps
Journal:  J Infect Dis       Date:  1972-04       Impact factor: 5.226

2.  Correlation between measurements of the luminol-dependent chemiluminescence response and bacterial susceptibility to phagocytosis.

Authors:  W D Welch
Journal:  Infect Immun       Date:  1980-11       Impact factor: 3.441

3.  alpha-Haemolysin: an additive virulence factor in Escherichia coli.

Authors:  L Emödy; T Pál; N V Safonova; B Kuch; N K Golutva
Journal:  Acta Microbiol Acad Sci Hung       Date:  1980

4.  Hemolytic activity in enterotoxigenic and non-enterotoxigenic strains of Escherichia coli.

Authors:  J M DeBoy; I K Wachsmuth; B R Davis
Journal:  J Clin Microbiol       Date:  1980-08       Impact factor: 5.948

5.  Activation of human neutrophil metabolism by streptolysin O.

Authors:  B R Andersen; J L Duncan
Journal:  J Infect Dis       Date:  1980-05       Impact factor: 5.226

6.  Observations on the pathogenic properties of the K88, Hly and Ent plasmids of Escherichia coli with particular reference to porcine diarrhoea.

Authors:  H W Smith; M A Linggood
Journal:  J Med Microbiol       Date:  1971-11       Impact factor: 2.472

7.  Association of hemolysin production, hemagglutination of human erythrocytes, and virulence for chicken embryos of extraintestinal Escherichia coli isolates.

Authors:  B H Minshew; J Jorgensen; G W Counts; S Falkow
Journal:  Infect Immun       Date:  1978-04       Impact factor: 3.441

8.  Some characteristics of Escherichia coli strains isolated from extraintestinal infections of humans.

Authors:  B H Minshew; J Jorgensen; M Swanstrum; G A Grootes-Reuvecamp; S Falkow
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

9.  [K antigen, colonization factor antigen, dulcitol fermentation, and hemolysin production in E. coli rough strains isolated from urine specimens (author's transl)].

Authors:  W Nimmich; G Naumann; E Budde; E Straube
Journal:  Zentralbl Bakteriol A       Date:  1980-06

10.  Cytotoxic activity of partially purified Escherichia coli alpha haemolysin.

Authors:  S J Cavalieri; I S Snyder
Journal:  J Med Microbiol       Date:  1982-02       Impact factor: 2.472

View more
  50 in total

1.  Haemophilus ducreyi inhibits phagocytosis by U-937 cells, a human macrophage-like cell line.

Authors:  G E Wood; S M Dutro; P A Totten
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Hemolytic activity in the periodontopathogen Porphyromonas gingivalis: kinetics of enzyme release and localization.

Authors:  L Chu; T E Bramanti; J L Ebersole; S C Holt
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

3.  Characterization of monoclonal antibodies against the Escherichia coli hemolysin.

Authors:  S Pellett; D F Boehm; I S Snyder; G Rowe; R A Welch
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

4.  Antibodies against hemolysin and cytotoxic necrotizing factor type 1 (CNF1) reduce bladder inflammation in a mouse model of urinary tract infection with toxigenic uropathogenic Escherichia coli.

Authors:  Mark A Smith; Rebecca A Weingarten; Lisa M Russo; Christy L Ventura; Alison D O'Brien
Journal:  Infect Immun       Date:  2015-02-09       Impact factor: 3.441

5.  Nucleotide sequence of an Escherichia coli chromosomal hemolysin.

Authors:  T Felmlee; S Pellett; R A Welch
Journal:  J Bacteriol       Date:  1985-07       Impact factor: 3.490

6.  A cytolysin encoded by Salmonella is required for survival within macrophages.

Authors:  S J Libby; W Goebel; A Ludwig; N Buchmeier; F Bowe; F C Fang; D G Guiney; J G Songer; F Heffron
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

7.  Hemolytically active (acylated) alpha-hemolysin elicits interleukin-1beta (IL-1beta) but augments the lethality of Escherichia coli by an IL-1- and tumor necrosis factor-independent mechanism.

Authors:  T G Gleason; C W Houlgrave; A K May; T D Crabtree; R G Sawyer; W Denham; J G Norman; T L Pruett
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

8.  Cloning and characterization of hemolytic genes from Helicobacter pylori.

Authors:  E S Drazek; A Dubois; R K Holmes; D Kersulyte; N S Akopyants; D E Berg; R L Warren
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

9.  In vivo effects of intravascularly applied Escherichia coli hemolysin: dissociation between induction of granulocytopenia and lethality in monkeys.

Authors:  D Vagts; H P Dienes; P J Barth; H Ronneberger; K D Hungerer; S Bhakdi
Journal:  Med Microbiol Immunol       Date:  1993-03       Impact factor: 3.402

10.  In vitro cytotoxic effect of alpha-hemolytic Escherichia coli on human blood granulocytes.

Authors:  O V Gadeberg; I Orskov
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.